NASDAQ$CVRX
CVRx Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
CVRx's Q3 2022 performance was marked by significant revenue growth, driven by increased adoption and utilization of Barostim, particularly in the U.S. heart failure market.
CVRx reported strong financial results for Q3 2022, with revenue increasing by 82% compared to the prior year. U.S. revenue saw a substantial increase of 96%, driven by growth in the heart failure segment. The company is also progressing with its BeAT-HF clinical trial and expects to share data in the first half of 2023.
- Total revenue reached $6.2 million, an 82% increase year-over-year.
- U.S. revenue increased by 96% to $5.0 million, with U.S. Heart Failure revenue nearly doubling.
- Gross profit increased by 92% to $4.8 million, with gross margin improving to 78%.
- The company had 91 active implanting centers as of September 30, 2022, compared to 38 in the prior year.
Headline financials
Revenue & EPS history
CVRx · Revenue · Quarterly
$6.19M
Forward guidance
The Company expects to report total revenue between $6.5 million and $7.0 million for the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+36.7%
Q3 2024
Best reaction
-39.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.7% | -13.3% | -29.2% | |
| Q4 2025 | -13.0% | -14.8% | +32.3% | |
| Q3 2025 | +0.8% | -3.4% | -8.5% | |
| Q1 2025 | -39.0% | -32.0% | -15.7% | |
| Q4 2024 | -7.2% | -8.4% | -28.8% | |
| Q3 2024 | +36.7% | +30.2% | +48.8% | |
| Q2 2024 | -17.5% | -14.4% | +3.3% | |
| Q1 2024 | -33.8% | -39.7% | -55.0% | |
| Q4 2023 | -1.4% | -6.1% | -19.6% | |
| Q3 2023 | -1.2% | +0.5% | +50.4% | |
| Q2 2023 | +6.2% | +5.7% | +2.3% | |
| Q1 2023 | +24.0% | +34.2% | +41.1% | |
| Q4 2022 | +3.1% | +5.9% | -24.2% | |
| Q3 2022 | +2.7% | +21.4% | +43.1% | |
| Q2 2022 | +22.1% | +24.6% | +4.6% | |
| Q1 2021 | -3.4% | -12.0% | -6.3% | |
| Q1 2022 | +12.6% | +28.5% | +14.0% | |
| Q4 2021 | +0.9% | +0.0% | -21.2% | |
| Q3 2021 | +4.8% | +4.1% | -36.5% | |
| Q2 2020 | -4.7% | -13.0% | -13.0% | |
| Q2 2021 | -5.6% | -7.5% | -15.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro